| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anus Neoplasms | 43 | 2024 | 411 | 13.170 |
Why?
|
| Colorectal Neoplasms | 106 | 2024 | 3578 | 10.870 |
Why?
|
| Rectal Neoplasms | 35 | 2024 | 1202 | 4.690 |
Why?
|
| Carcinoma, Squamous Cell | 35 | 2024 | 5437 | 4.430 |
Why?
|
| Appendiceal Neoplasms | 17 | 2023 | 234 | 3.030 |
Why?
|
| Antineoplastic Agents | 47 | 2023 | 14289 | 2.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 60 | 2023 | 15862 | 2.420 |
Why?
|
| Camptothecin | 19 | 2020 | 517 | 1.850 |
Why?
|
| Cetuximab | 19 | 2022 | 472 | 1.820 |
Why?
|
| Chemoradiotherapy | 17 | 2023 | 1946 | 1.800 |
Why?
|
| Colonic Neoplasms | 12 | 2024 | 1390 | 1.770 |
Why?
|
| Adenocarcinoma | 34 | 2023 | 7789 | 1.700 |
Why?
|
| Peritoneal Neoplasms | 9 | 2021 | 821 | 1.680 |
Why?
|
| Antibodies, Monoclonal | 28 | 2022 | 4367 | 1.670 |
Why?
|
| Fluorouracil | 35 | 2023 | 1944 | 1.550 |
Why?
|
| Angiogenesis Inhibitors | 10 | 2022 | 1248 | 1.490 |
Why?
|
| Proto-Oncogene Proteins B-raf | 12 | 2023 | 1283 | 1.460 |
Why?
|
| Anal Canal | 10 | 2024 | 238 | 1.400 |
Why?
|
| Liver Neoplasms | 29 | 2022 | 4557 | 1.360 |
Why?
|
| Humans | 239 | 2024 | 261506 | 1.360 |
Why?
|
| Metastasectomy | 4 | 2021 | 200 | 1.290 |
Why?
|
| Organoplatinum Compounds | 26 | 2020 | 702 | 1.240 |
Why?
|
| Bevacizumab | 22 | 2020 | 938 | 1.180 |
Why?
|
| Papillomavirus Infections | 6 | 2023 | 980 | 1.130 |
Why?
|
| Microsatellite Instability | 8 | 2023 | 400 | 1.100 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2019 | 1249 | 1.090 |
Why?
|
| Adenocarcinoma, Mucinous | 7 | 2023 | 436 | 1.090 |
Why?
|
| ErbB Receptors | 13 | 2020 | 2295 | 1.080 |
Why?
|
| Carcinoma | 6 | 2022 | 2578 | 1.040 |
Why?
|
| Benzofurans | 2 | 2024 | 38 | 1.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 16 | 2023 | 1331 | 1.010 |
Why?
|
| ras Proteins | 9 | 2020 | 770 | 0.980 |
Why?
|
| Salvage Therapy | 6 | 2021 | 2054 | 0.970 |
Why?
|
| Middle Aged | 133 | 2023 | 86204 | 0.940 |
Why?
|
| Circulating Tumor DNA | 2 | 2024 | 235 | 0.930 |
Why?
|
| Medical Oncology | 8 | 2023 | 1423 | 0.920 |
Why?
|
| Aged | 114 | 2023 | 70117 | 0.910 |
Why?
|
| Drugs, Investigational | 2 | 2018 | 135 | 0.910 |
Why?
|
| Survival Rate | 39 | 2020 | 12221 | 0.910 |
Why?
|
| Male | 144 | 2023 | 123000 | 0.890 |
Why?
|
| Neoplasm Metastasis | 26 | 2020 | 5112 | 0.860 |
Why?
|
| Female | 146 | 2023 | 141928 | 0.850 |
Why?
|
| Biomarkers, Tumor | 23 | 2024 | 10331 | 0.840 |
Why?
|
| Hyperthermia, Induced | 5 | 2019 | 510 | 0.810 |
Why?
|
| Peripheral Nervous System Diseases | 7 | 2022 | 393 | 0.790 |
Why?
|
| Adult | 99 | 2022 | 77950 | 0.790 |
Why?
|
| Trifluridine | 2 | 2023 | 30 | 0.780 |
Why?
|
| Neoplasm Recurrence, Local | 26 | 2022 | 10035 | 0.780 |
Why?
|
| Immunotherapy | 8 | 2023 | 3341 | 0.780 |
Why?
|
| Gastrointestinal Neoplasms | 6 | 2023 | 600 | 0.750 |
Why?
|
| Combined Modality Therapy | 35 | 2020 | 8865 | 0.750 |
Why?
|
| Mutation | 27 | 2024 | 15179 | 0.750 |
Why?
|
| Pseudomyxoma Peritonei | 3 | 2015 | 38 | 0.750 |
Why?
|
| Hepatectomy | 14 | 2022 | 1011 | 0.740 |
Why?
|
| Genomics | 6 | 2022 | 2738 | 0.710 |
Why?
|
| Carcinoma, Signet Ring Cell | 3 | 2019 | 170 | 0.710 |
Why?
|
| Neoplasms | 21 | 2023 | 15193 | 0.690 |
Why?
|
| Clinical Trials as Topic | 10 | 2019 | 3719 | 0.680 |
Why?
|
| Fertility Preservation | 1 | 2021 | 150 | 0.680 |
Why?
|
| Neoplasm Staging | 39 | 2023 | 13658 | 0.680 |
Why?
|
| Immunoconjugates | 1 | 2022 | 279 | 0.670 |
Why?
|
| Biological Products | 1 | 2022 | 274 | 0.670 |
Why?
|
| Prognosis | 36 | 2023 | 21713 | 0.670 |
Why?
|
| Quinazolines | 4 | 2024 | 923 | 0.670 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 246 | 0.660 |
Why?
|
| Capecitabine | 13 | 2019 | 388 | 0.650 |
Why?
|
| Antimetabolites, Antineoplastic | 6 | 2020 | 1299 | 0.630 |
Why?
|
| Antibodies, Monoclonal, Humanized | 25 | 2020 | 3251 | 0.630 |
Why?
|
| Minocycline | 1 | 2019 | 182 | 0.620 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 469 | 0.610 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2014 | 2488 | 0.600 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2017 | 5178 | 0.600 |
Why?
|
| Deoxycytidine | 13 | 2014 | 1353 | 0.590 |
Why?
|
| Leucovorin | 12 | 2023 | 332 | 0.580 |
Why?
|
| DNA Polymerase II | 1 | 2016 | 59 | 0.560 |
Why?
|
| Disease-Free Survival | 31 | 2020 | 10001 | 0.560 |
Why?
|
| Phenylurea Compounds | 3 | 2019 | 580 | 0.560 |
Why?
|
| Cisplatin | 8 | 2022 | 2432 | 0.560 |
Why?
|
| Pyrrolidinones | 1 | 2016 | 61 | 0.550 |
Why?
|
| Receptor, TIE-1 | 1 | 2015 | 7 | 0.540 |
Why?
|
| Pyridines | 5 | 2019 | 1244 | 0.540 |
Why?
|
| Neoadjuvant Therapy | 19 | 2023 | 4975 | 0.530 |
Why?
|
| Lymphatic Metastasis | 10 | 2018 | 4844 | 0.530 |
Why?
|
| Physicians | 2 | 2021 | 882 | 0.510 |
Why?
|
| Retrospective Studies | 48 | 2022 | 37905 | 0.490 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2016 | 222 | 0.480 |
Why?
|
| Treatment Outcome | 45 | 2022 | 32848 | 0.480 |
Why?
|
| Aged, 80 and over | 48 | 2023 | 29902 | 0.470 |
Why?
|
| Molecular Targeted Therapy | 5 | 2017 | 2330 | 0.460 |
Why?
|
| Liver Transplantation | 1 | 2022 | 1112 | 0.450 |
Why?
|
| Follow-Up Studies | 26 | 2020 | 14889 | 0.450 |
Why?
|
| Incidence | 14 | 2021 | 5673 | 0.450 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1910 | 0.450 |
Why?
|
| Fatigue | 1 | 2019 | 1239 | 0.440 |
Why?
|
| Quinolines | 1 | 2016 | 383 | 0.440 |
Why?
|
| Age of Onset | 4 | 2022 | 827 | 0.430 |
Why?
|
| HIV Infections | 3 | 2022 | 2134 | 0.430 |
Why?
|
| Fetus | 1 | 2016 | 601 | 0.420 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 651 | 0.420 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2021 | 2594 | 0.420 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 4757 | 0.410 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 715 | 0.410 |
Why?
|
| Young Adult | 22 | 2021 | 21445 | 0.410 |
Why?
|
| Chemotherapy, Adjuvant | 14 | 2017 | 3890 | 0.400 |
Why?
|
| Rare Diseases | 3 | 2022 | 351 | 0.390 |
Why?
|
| High-Throughput Nucleotide Sequencing | 7 | 2024 | 2291 | 0.390 |
Why?
|
| Kaplan-Meier Estimate | 12 | 2021 | 6207 | 0.390 |
Why?
|
| Patient Participation | 1 | 2015 | 446 | 0.380 |
Why?
|
| Herbal Medicine | 1 | 2010 | 11 | 0.380 |
Why?
|
| Clinical Trials, Phase III as Topic | 4 | 2022 | 447 | 0.380 |
Why?
|
| Ovariectomy | 1 | 2012 | 330 | 0.380 |
Why?
|
| Prospective Studies | 10 | 2023 | 12873 | 0.360 |
Why?
|
| Gene Expression Profiling | 4 | 2018 | 5159 | 0.350 |
Why?
|
| Pandemics | 5 | 2020 | 1559 | 0.340 |
Why?
|
| Double-Blind Method | 5 | 2023 | 2588 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 5 | 2021 | 5061 | 0.330 |
Why?
|
| Palliative Care | 3 | 2021 | 2037 | 0.330 |
Why?
|
| Time Factors | 17 | 2021 | 12926 | 0.330 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 1763 | 0.320 |
Why?
|
| Cytoreduction Surgical Procedures | 3 | 2017 | 475 | 0.320 |
Why?
|
| Age Factors | 8 | 2021 | 5377 | 0.320 |
Why?
|
| Antiemetics | 2 | 2020 | 125 | 0.310 |
Why?
|
| Cell-Free Nucleic Acids | 3 | 2019 | 224 | 0.310 |
Why?
|
| Neurofeedback | 2 | 2018 | 19 | 0.310 |
Why?
|
| Gastrointestinal Tract | 1 | 2010 | 324 | 0.300 |
Why?
|
| Quality of Life | 9 | 2023 | 4532 | 0.300 |
Why?
|
| Gallbladder Neoplasms | 2 | 2011 | 245 | 0.300 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2023 | 1533 | 0.290 |
Why?
|
| SEER Program | 7 | 2021 | 1000 | 0.290 |
Why?
|
| Genes, ras | 2 | 2020 | 667 | 0.290 |
Why?
|
| Drug Eruptions | 1 | 2009 | 256 | 0.290 |
Why?
|
| Survival Analysis | 17 | 2023 | 9180 | 0.290 |
Why?
|
| Standard of Care | 2 | 2023 | 243 | 0.290 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 2992 | 0.290 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2022 | 2104 | 0.280 |
Why?
|
| Multicenter Studies as Topic | 3 | 2021 | 543 | 0.280 |
Why?
|
| Mitomycin | 4 | 2022 | 208 | 0.280 |
Why?
|
| Drug Delivery Systems | 2 | 2007 | 669 | 0.270 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2010 | 852 | 0.270 |
Why?
|
| Re-Irradiation | 2 | 2018 | 163 | 0.270 |
Why?
|
| Mass Screening | 1 | 2014 | 1509 | 0.270 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2012 | 1546 | 0.270 |
Why?
|
| Neoplasm Proteins | 3 | 2017 | 3230 | 0.270 |
Why?
|
| Cholangiocarcinoma | 3 | 2012 | 493 | 0.260 |
Why?
|
| Lung Neoplasms | 9 | 2022 | 11538 | 0.250 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2020 | 521 | 0.250 |
Why?
|
| Papillomavirus Vaccines | 2 | 2018 | 195 | 0.250 |
Why?
|
| Colectomy | 5 | 2018 | 288 | 0.250 |
Why?
|
| Epothilones | 1 | 2004 | 54 | 0.240 |
Why?
|
| United States | 14 | 2023 | 15433 | 0.240 |
Why?
|
| Exosomes | 2 | 2017 | 253 | 0.240 |
Why?
|
| Laparoscopy | 3 | 2018 | 1225 | 0.240 |
Why?
|
| Appendix | 2 | 2021 | 41 | 0.240 |
Why?
|
| Digestive System Surgical Procedures | 3 | 2012 | 275 | 0.240 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 3101 | 0.240 |
Why?
|
| DNA Methylation | 3 | 2019 | 2669 | 0.230 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2018 | 4549 | 0.230 |
Why?
|
| Neoplasm Grading | 6 | 2020 | 1742 | 0.230 |
Why?
|
| DNA Mismatch Repair | 2 | 2023 | 268 | 0.230 |
Why?
|
| Liquid Biopsy | 3 | 2020 | 158 | 0.230 |
Why?
|
| Genes, Neoplasm | 2 | 2023 | 324 | 0.220 |
Why?
|
| Betacoronavirus | 4 | 2020 | 527 | 0.220 |
Why?
|
| Risk Assessment | 12 | 2020 | 6869 | 0.220 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2023 | 133 | 0.210 |
Why?
|
| Cell Cycle Proteins | 1 | 2011 | 2045 | 0.210 |
Why?
|
| Endothelial Growth Factors | 1 | 2022 | 197 | 0.210 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 2 | 2023 | 83 | 0.210 |
Why?
|
| Carboplatin | 3 | 2020 | 823 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2018 | 5539 | 0.200 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2022 | 96 | 0.200 |
Why?
|
| Administration, Cutaneous | 1 | 2021 | 141 | 0.200 |
Why?
|
| Colon, Sigmoid | 1 | 2021 | 42 | 0.200 |
Why?
|
| Oncologists | 2 | 2020 | 134 | 0.200 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 4988 | 0.200 |
Why?
|
| Paclitaxel | 5 | 2022 | 1996 | 0.200 |
Why?
|
| Bile Duct Neoplasms | 2 | 2012 | 493 | 0.200 |
Why?
|
| Reproductive Health | 1 | 2021 | 46 | 0.200 |
Why?
|
| Risk Factors | 14 | 2019 | 17523 | 0.190 |
Why?
|
| Clinical Trials, Phase II as Topic | 4 | 2012 | 665 | 0.190 |
Why?
|
| Splenic Infarction | 1 | 2020 | 14 | 0.190 |
Why?
|
| Conserved Sequence | 2 | 2012 | 469 | 0.190 |
Why?
|
| Hypersplenism | 1 | 2020 | 23 | 0.190 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2020 | 26 | 0.190 |
Why?
|
| Feasibility Studies | 3 | 2022 | 2292 | 0.180 |
Why?
|
| Treatment Failure | 3 | 2017 | 1391 | 0.180 |
Why?
|
| Drug Administration Schedule | 7 | 2020 | 3472 | 0.180 |
Why?
|
| Uracil | 1 | 2020 | 64 | 0.180 |
Why?
|
| Febrile Neutropenia | 1 | 2020 | 65 | 0.180 |
Why?
|
| Thymine | 1 | 2020 | 46 | 0.180 |
Why?
|
| Melatonin | 1 | 2020 | 46 | 0.180 |
Why?
|
| Pyrrolidines | 1 | 2020 | 113 | 0.180 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 53 | 0.180 |
Why?
|
| Patient Selection | 6 | 2020 | 2055 | 0.170 |
Why?
|
| Phototherapy | 1 | 2020 | 75 | 0.170 |
Why?
|
| Endoscopy | 1 | 2022 | 479 | 0.170 |
Why?
|
| Documentation | 1 | 2021 | 207 | 0.170 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2020 | 3552 | 0.170 |
Why?
|
| Polypharmacy | 1 | 2019 | 57 | 0.170 |
Why?
|
| Glutamine | 1 | 2021 | 299 | 0.170 |
Why?
|
| Methylphenidate | 1 | 2020 | 103 | 0.170 |
Why?
|
| Radiotherapy | 5 | 2011 | 1824 | 0.170 |
Why?
|
| Patient Care | 1 | 2020 | 149 | 0.170 |
Why?
|
| Chemoradiotherapy, Adjuvant | 4 | 2017 | 565 | 0.170 |
Why?
|
| Ovarian Neoplasms | 2 | 2012 | 4638 | 0.170 |
Why?
|
| Azetidines | 1 | 2019 | 87 | 0.170 |
Why?
|
| Human papillomavirus 16 | 2 | 2023 | 256 | 0.170 |
Why?
|
| DNA | 3 | 2017 | 2693 | 0.170 |
Why?
|
| Disease Progression | 8 | 2017 | 6682 | 0.170 |
Why?
|
| Health Status Indicators | 2 | 2010 | 224 | 0.170 |
Why?
|
| Prodrugs | 1 | 2020 | 217 | 0.160 |
Why?
|
| Minority Groups | 1 | 2021 | 322 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2017 | 7551 | 0.160 |
Why?
|
| Metformin | 2 | 2013 | 378 | 0.160 |
Why?
|
| Fertility | 1 | 2021 | 336 | 0.160 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2019 | 169 | 0.160 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2020 | 134 | 0.160 |
Why?
|
| Central Nervous System Stimulants | 1 | 2020 | 225 | 0.160 |
Why?
|
| Hypoglycemic Agents | 2 | 2013 | 586 | 0.160 |
Why?
|
| Drug Combinations | 1 | 2020 | 621 | 0.160 |
Why?
|
| Disease Management | 2 | 2019 | 1052 | 0.160 |
Why?
|
| Geriatric Assessment | 1 | 2019 | 275 | 0.160 |
Why?
|
| Deglutition Disorders | 1 | 2022 | 447 | 0.160 |
Why?
|
| Patient-Specific Modeling | 1 | 2017 | 28 | 0.150 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2017 | 84 | 0.150 |
Why?
|
| Neoplasm, Residual | 3 | 2020 | 1656 | 0.150 |
Why?
|
| Cancer Survivors | 2 | 2022 | 650 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2019 | 8873 | 0.150 |
Why?
|
| Pyrazines | 2 | 2018 | 495 | 0.150 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2011 | 2231 | 0.150 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2018 | 174 | 0.150 |
Why?
|
| Nutritional Status | 1 | 2019 | 337 | 0.150 |
Why?
|
| Symptom Assessment | 1 | 2019 | 267 | 0.150 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 2011 | 363 | 0.150 |
Why?
|
| GTP Phosphohydrolases | 1 | 2019 | 336 | 0.150 |
Why?
|
| Mutation Rate | 1 | 2017 | 223 | 0.140 |
Why?
|
| Pelvic Neoplasms | 1 | 2018 | 189 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2019 | 1163 | 0.140 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2017 | 160 | 0.140 |
Why?
|
| Neuroendocrine Tumors | 2 | 2021 | 634 | 0.140 |
Why?
|
| Case-Control Studies | 5 | 2017 | 6100 | 0.140 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2015 | 222 | 0.140 |
Why?
|
| PPAR delta | 1 | 2017 | 55 | 0.140 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 538 | 0.140 |
Why?
|
| Delivery of Health Care | 1 | 2023 | 860 | 0.140 |
Why?
|
| Paresthesia | 1 | 2016 | 33 | 0.140 |
Why?
|
| Radiation, Ionizing | 1 | 2017 | 187 | 0.140 |
Why?
|
| Drug Design | 1 | 2018 | 375 | 0.140 |
Why?
|
| Prevalence | 2 | 2022 | 3260 | 0.140 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2016 | 89 | 0.140 |
Why?
|
| Touch | 1 | 2016 | 71 | 0.130 |
Why?
|
| Microbiota | 1 | 2022 | 547 | 0.130 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2022 | 1048 | 0.130 |
Why?
|
| Human papillomavirus 18 | 1 | 2015 | 43 | 0.130 |
Why?
|
| Depression | 3 | 2019 | 1715 | 0.130 |
Why?
|
| Hepatitis B, Chronic | 1 | 2017 | 137 | 0.130 |
Why?
|
| Vomiting | 1 | 2017 | 354 | 0.130 |
Why?
|
| Vimentin | 1 | 2016 | 253 | 0.130 |
Why?
|
| Nausea | 1 | 2017 | 525 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 551 | 0.130 |
Why?
|
| Adolescent | 11 | 2021 | 31252 | 0.130 |
Why?
|
| Hepatitis B virus | 1 | 2017 | 217 | 0.130 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1022 | 0.130 |
Why?
|
| Polyurethanes | 1 | 2014 | 36 | 0.130 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2017 | 489 | 0.130 |
Why?
|
| Colonic Polyps | 1 | 2017 | 209 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2012 | 2054 | 0.130 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2017 | 316 | 0.130 |
Why?
|
| Patient Advocacy | 1 | 2015 | 92 | 0.120 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 1085 | 0.120 |
Why?
|
| CA-19-9 Antigen | 1 | 2015 | 144 | 0.120 |
Why?
|
| Thioctic Acid | 1 | 2013 | 12 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2017 | 478 | 0.120 |
Why?
|
| Neoplasm Transplantation | 1 | 2017 | 1519 | 0.120 |
Why?
|
| Aorta | 1 | 2018 | 692 | 0.120 |
Why?
|
| Calcinosis | 1 | 2017 | 423 | 0.120 |
Why?
|
| Survivors | 2 | 2017 | 1031 | 0.120 |
Why?
|
| Psychometrics | 2 | 2010 | 937 | 0.120 |
Why?
|
| Vinblastine | 1 | 2014 | 453 | 0.120 |
Why?
|
| Specialization | 1 | 2015 | 130 | 0.120 |
Why?
|
| Tumor Burden | 3 | 2015 | 1987 | 0.120 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1350 | 0.120 |
Why?
|
| Piperidines | 1 | 2019 | 1035 | 0.120 |
Why?
|
| Colostomy | 1 | 2013 | 70 | 0.120 |
Why?
|
| Gene Amplification | 1 | 2016 | 731 | 0.110 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 1037 | 0.110 |
Why?
|
| Dasatinib | 1 | 2017 | 862 | 0.110 |
Why?
|
| Mandibular Neoplasms | 1 | 2013 | 76 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2016 | 419 | 0.110 |
Why?
|
| Animals | 7 | 2017 | 59536 | 0.110 |
Why?
|
| Injections, Intraperitoneal | 2 | 2010 | 197 | 0.110 |
Why?
|
| Preoperative Care | 3 | 2014 | 1529 | 0.110 |
Why?
|
| Medical Errors | 1 | 2015 | 219 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2017 | 519 | 0.110 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 4849 | 0.110 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2013 | 113 | 0.110 |
Why?
|
| Databases, Factual | 4 | 2022 | 2218 | 0.110 |
Why?
|
| Phosphorylcholine | 1 | 2012 | 54 | 0.110 |
Why?
|
| Genetic Markers | 2 | 2018 | 974 | 0.110 |
Why?
|
| Scalp | 1 | 2013 | 156 | 0.100 |
Why?
|
| Adenoma | 1 | 2017 | 716 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2022 | 2403 | 0.100 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2013 | 1362 | 0.100 |
Why?
|
| Lymphocytes | 1 | 2017 | 1234 | 0.100 |
Why?
|
| Recurrence | 4 | 2016 | 4758 | 0.100 |
Why?
|
| Robotic Surgical Procedures | 1 | 2018 | 481 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2017 | 1152 | 0.100 |
Why?
|
| Pyrazoles | 2 | 2018 | 1471 | 0.100 |
Why?
|
| National Cancer Institute (U.S.) | 2 | 2023 | 211 | 0.100 |
Why?
|
| Multivariate Analysis | 7 | 2017 | 4298 | 0.100 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 1258 | 0.100 |
Why?
|
| Diagnostic Imaging | 1 | 2019 | 1162 | 0.100 |
Why?
|
| Therapies, Investigational | 1 | 2011 | 62 | 0.100 |
Why?
|
| MicroRNAs | 2 | 2016 | 2947 | 0.100 |
Why?
|
| Poly-ADP-Ribose Binding Proteins | 1 | 2011 | 109 | 0.100 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2011 | 206 | 0.100 |
Why?
|
| Pyrimidines | 3 | 2020 | 3518 | 0.100 |
Why?
|
| Cohort Studies | 7 | 2019 | 9244 | 0.100 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 2 | 2020 | 43 | 0.100 |
Why?
|
| Epoxide Hydrolases | 1 | 2010 | 53 | 0.100 |
Why?
|
| Keratins | 1 | 2011 | 330 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2019 | 2819 | 0.090 |
Why?
|
| Chromogranins | 2 | 2020 | 84 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 195 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2012 | 503 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 2 | 2022 | 3976 | 0.090 |
Why?
|
| Acute Lung Injury | 1 | 2011 | 92 | 0.090 |
Why?
|
| Proteomics | 1 | 2017 | 1380 | 0.090 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2010 | 102 | 0.090 |
Why?
|
| Pulmonary Alveoli | 1 | 2011 | 208 | 0.090 |
Why?
|
| Antiviral Agents | 1 | 2017 | 1230 | 0.090 |
Why?
|
| Vaccination | 1 | 2016 | 1123 | 0.090 |
Why?
|
| Splenomegaly | 1 | 2010 | 158 | 0.090 |
Why?
|
| Radiotherapy Dosage | 7 | 2013 | 3842 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2013 | 1678 | 0.090 |
Why?
|
| Complementary Therapies | 1 | 2010 | 126 | 0.080 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2010 | 122 | 0.080 |
Why?
|
| DNA Repair | 1 | 2017 | 1872 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 761 | 0.080 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2009 | 106 | 0.080 |
Why?
|
| Precision Medicine | 2 | 2017 | 1154 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2018 | 2265 | 0.080 |
Why?
|
| Sacrum | 1 | 2009 | 132 | 0.080 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2007 | 32 | 0.080 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 7548 | 0.080 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2009 | 145 | 0.080 |
Why?
|
| Ampulla of Vater | 1 | 2009 | 155 | 0.080 |
Why?
|
| Respiratory Insufficiency | 1 | 2011 | 330 | 0.080 |
Why?
|
| Duodenal Neoplasms | 1 | 2008 | 138 | 0.080 |
Why?
|
| Spinal Fractures | 1 | 2009 | 132 | 0.080 |
Why?
|
| Paper | 1 | 2007 | 11 | 0.080 |
Why?
|
| Retreatment | 3 | 2018 | 452 | 0.080 |
Why?
|
| Consensus | 2 | 2023 | 978 | 0.070 |
Why?
|
| Ki-67 Antigen | 1 | 2009 | 666 | 0.070 |
Why?
|
| Intestinal Neoplasms | 1 | 2009 | 189 | 0.070 |
Why?
|
| Drug Approval | 1 | 2008 | 178 | 0.070 |
Why?
|
| Intestinal Perforation | 1 | 2007 | 102 | 0.070 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2011 | 607 | 0.070 |
Why?
|
| Yttrium Radioisotopes | 1 | 2007 | 178 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2008 | 332 | 0.070 |
Why?
|
| Hedgehog Proteins | 1 | 2009 | 424 | 0.070 |
Why?
|
| Maximum Tolerated Dose | 3 | 2017 | 1290 | 0.070 |
Why?
|
| Mice | 4 | 2017 | 34495 | 0.070 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2013 | 882 | 0.070 |
Why?
|
| Computers, Handheld | 1 | 2007 | 69 | 0.070 |
Why?
|
| Sickness Impact Profile | 1 | 2007 | 139 | 0.070 |
Why?
|
| International Cooperation | 2 | 2020 | 323 | 0.070 |
Why?
|
| Texas | 6 | 2018 | 6311 | 0.070 |
Why?
|
| Cause of Death | 1 | 2009 | 752 | 0.070 |
Why?
|
| Writing | 1 | 2007 | 104 | 0.070 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2011 | 854 | 0.070 |
Why?
|
| Cross-Over Studies | 2 | 2023 | 460 | 0.070 |
Why?
|
| Sex Factors | 4 | 2016 | 2139 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2009 | 726 | 0.070 |
Why?
|
| Surveys and Questionnaires | 4 | 2017 | 5687 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 1870 | 0.070 |
Why?
|
| T-Lymphocytes | 1 | 2018 | 3869 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2009 | 499 | 0.070 |
Why?
|
| Colon | 2 | 2020 | 670 | 0.060 |
Why?
|
| Radiation Injuries | 2 | 2010 | 1411 | 0.060 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2016 | 1833 | 0.060 |
Why?
|
| Genotype | 4 | 2018 | 4109 | 0.060 |
Why?
|
| Platelet Count | 2 | 2020 | 490 | 0.060 |
Why?
|
| Biomarkers | 1 | 2016 | 5047 | 0.060 |
Why?
|
| Neutropenia | 1 | 2009 | 968 | 0.060 |
Why?
|
| Obesity | 1 | 2017 | 2884 | 0.060 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2011 | 1439 | 0.060 |
Why?
|
| Phthalazines | 1 | 2006 | 253 | 0.060 |
Why?
|
| Fatty Liver | 1 | 2006 | 235 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2006 | 355 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2017 | 4821 | 0.060 |
Why?
|
| Catheter Ablation | 1 | 2009 | 620 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2008 | 649 | 0.060 |
Why?
|
| Spleen | 2 | 2020 | 676 | 0.060 |
Why?
|
| Chi-Square Distribution | 3 | 2013 | 1323 | 0.060 |
Why?
|
| Societies, Medical | 2 | 2023 | 1335 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 4938 | 0.060 |
Why?
|
| Genetic Variation | 1 | 2012 | 2086 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2022 | 2803 | 0.060 |
Why?
|
| Angiogenesis Inducing Agents | 2 | 2017 | 106 | 0.060 |
Why?
|
| Papillomavirus E7 Proteins | 1 | 2023 | 64 | 0.060 |
Why?
|
| Age Distribution | 2 | 2017 | 698 | 0.060 |
Why?
|
| Massage | 1 | 2022 | 15 | 0.060 |
Why?
|
| Pregnancy | 1 | 2016 | 7573 | 0.060 |
Why?
|
| HLA-A Antigens | 1 | 2023 | 102 | 0.050 |
Why?
|
| Carcinoma in Situ | 1 | 2006 | 487 | 0.050 |
Why?
|
| Breast Neoplasms | 3 | 2018 | 15694 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2013 | 1866 | 0.050 |
Why?
|
| Liver Diseases | 1 | 2007 | 574 | 0.050 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2022 | 59 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2007 | 1301 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2009 | 1549 | 0.050 |
Why?
|
| Genetic Testing | 2 | 2022 | 1589 | 0.050 |
Why?
|
| Infusions, Parenteral | 2 | 2013 | 191 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2017 | 4892 | 0.050 |
Why?
|
| Research Design | 2 | 2022 | 1544 | 0.050 |
Why?
|
| Technology | 1 | 2022 | 96 | 0.050 |
Why?
|
| Biopsy | 2 | 2020 | 3443 | 0.050 |
Why?
|
| Risk | 2 | 2017 | 1972 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2022 | 276 | 0.050 |
Why?
|
| Smoking | 1 | 2010 | 2440 | 0.050 |
Why?
|
| Pharmacogenomic Variants | 1 | 2020 | 29 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2022 | 575 | 0.050 |
Why?
|
| Hand Hygiene | 1 | 2020 | 14 | 0.050 |
Why?
|
| Food-Drug Interactions | 1 | 2020 | 22 | 0.050 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 44 | 0.050 |
Why?
|
| Pyrimidinones | 1 | 2022 | 314 | 0.050 |
Why?
|
| International Agencies | 1 | 2020 | 107 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2023 | 417 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 490 | 0.050 |
Why?
|
| Resource Allocation | 1 | 2020 | 67 | 0.050 |
Why?
|
| Lymph Nodes | 1 | 2011 | 2967 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2023 | 709 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2008 | 11965 | 0.040 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 1756 | 0.040 |
Why?
|
| Pyridones | 1 | 2022 | 348 | 0.040 |
Why?
|
| Logistic Models | 2 | 2017 | 3441 | 0.040 |
Why?
|
| Nuclear Proteins | 1 | 2011 | 3343 | 0.040 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2019 | 98 | 0.040 |
Why?
|
| Hand-Assisted Laparoscopy | 1 | 2018 | 7 | 0.040 |
Why?
|
| World Health Organization | 1 | 2020 | 316 | 0.040 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2017 | 973 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 700 | 0.040 |
Why?
|
| Karnofsky Performance Status | 1 | 2018 | 175 | 0.040 |
Why?
|
| Smad4 Protein | 1 | 2019 | 196 | 0.040 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2020 | 221 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 270 | 0.040 |
Why?
|
| Drug Discovery | 1 | 2020 | 324 | 0.040 |
Why?
|
| Hypoxanthine | 1 | 2017 | 8 | 0.040 |
Why?
|
| Xanthine | 1 | 2017 | 11 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2018 | 210 | 0.040 |
Why?
|
| Remission Induction | 1 | 2004 | 3569 | 0.040 |
Why?
|
| Mannose | 1 | 2017 | 40 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2004 | 1547 | 0.040 |
Why?
|
| Intestinal Polyps | 1 | 2017 | 72 | 0.040 |
Why?
|
| Mutagenicity Tests | 1 | 2017 | 69 | 0.040 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 4654 | 0.040 |
Why?
|
| Caffeine | 1 | 2017 | 87 | 0.040 |
Why?
|
| Platinum Compounds | 1 | 2017 | 131 | 0.040 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2004 | 962 | 0.040 |
Why?
|
| Sleep | 1 | 2020 | 413 | 0.040 |
Why?
|
| Genetics, Medical | 1 | 2017 | 143 | 0.040 |
Why?
|
| Peritoneum | 1 | 2017 | 150 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.040 |
Why?
|
| Receptors, Immunologic | 1 | 2018 | 309 | 0.040 |
Why?
|
| Safety | 1 | 2018 | 465 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2017 | 348 | 0.030 |
Why?
|
| Adrenalectomy | 1 | 2017 | 188 | 0.030 |
Why?
|
| Patient Outcome Assessment | 1 | 2017 | 245 | 0.030 |
Why?
|
| Liver Failure | 1 | 2017 | 140 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2017 | 342 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2017 | 495 | 0.030 |
Why?
|
| Urea | 1 | 2017 | 290 | 0.030 |
Why?
|
| Appendectomy | 1 | 2016 | 124 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2020 | 710 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2017 | 756 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2012 | 7702 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2018 | 1053 | 0.030 |
Why?
|
| Thorax | 1 | 2016 | 213 | 0.030 |
Why?
|
| Rectum | 1 | 2017 | 467 | 0.030 |
Why?
|
| Organ Sparing Treatments | 1 | 2017 | 277 | 0.030 |
Why?
|
| Propensity Score | 1 | 2018 | 750 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2020 | 748 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2017 | 263 | 0.030 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2014 | 26 | 0.030 |
Why?
|
| Body Mass Index | 2 | 2017 | 2203 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2009 | 5270 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2017 | 368 | 0.030 |
Why?
|
| Abdomen | 1 | 2016 | 332 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 498 | 0.030 |
Why?
|
| Interleukin-8 | 1 | 2017 | 519 | 0.030 |
Why?
|
| CpG Islands | 1 | 2016 | 633 | 0.030 |
Why?
|
| Organs at Risk | 1 | 2017 | 514 | 0.030 |
Why?
|
| Codon | 1 | 2014 | 241 | 0.030 |
Why?
|
| Telemedicine | 1 | 2020 | 471 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2013 | 85 | 0.030 |
Why?
|
| Physician's Role | 1 | 2016 | 238 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 478 | 0.030 |
Why?
|
| Celecoxib | 1 | 2013 | 200 | 0.030 |
Why?
|
| Electroencephalography | 1 | 2018 | 898 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 1183 | 0.030 |
Why?
|
| Pain | 2 | 2014 | 1658 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 967 | 0.030 |
Why?
|
| Placebos | 1 | 2013 | 437 | 0.030 |
Why?
|
| Diploidy | 1 | 2012 | 114 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 621 | 0.030 |
Why?
|
| Skin Temperature | 1 | 2012 | 32 | 0.030 |
Why?
|
| Adrenal Glands | 1 | 2012 | 122 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2013 | 388 | 0.030 |
Why?
|
| Reoperation | 1 | 2016 | 1382 | 0.030 |
Why?
|
| Child | 3 | 2020 | 29154 | 0.030 |
Why?
|
| Sensation | 1 | 2012 | 71 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 915 | 0.030 |
Why?
|
| Gene Deletion | 1 | 2017 | 1442 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 2864 | 0.030 |
Why?
|
| Registries | 2 | 2009 | 2170 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 2074 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2017 | 2508 | 0.020 |
Why?
|
| Aneuploidy | 1 | 2012 | 369 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2013 | 483 | 0.020 |
Why?
|
| Eukaryotic Initiation Factor-3 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Leiomyosarcoma | 1 | 2012 | 223 | 0.020 |
Why?
|
| Ligands | 1 | 2013 | 995 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2232 | 0.020 |
Why?
|
| Bile Ducts, Intrahepatic | 1 | 2012 | 334 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 2352 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2018 | 1491 | 0.020 |
Why?
|
| Azacitidine | 1 | 2016 | 1149 | 0.020 |
Why?
|
| Bortezomib | 1 | 2012 | 543 | 0.020 |
Why?
|
| Boronic Acids | 1 | 2012 | 362 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 1084 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 2017 | 735 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2013 | 1544 | 0.020 |
Why?
|
| Niacinamide | 1 | 2011 | 421 | 0.020 |
Why?
|
| Histones | 1 | 2017 | 1466 | 0.020 |
Why?
|
| Medicare | 1 | 2014 | 860 | 0.020 |
Why?
|
| Pancreas | 1 | 2012 | 718 | 0.020 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2009 | 111 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2011 | 829 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 5114 | 0.020 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2010 | 129 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 2483 | 0.020 |
Why?
|
| Endosonography | 1 | 2012 | 536 | 0.020 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2009 | 129 | 0.020 |
Why?
|
| Gene Expression | 1 | 2017 | 3570 | 0.020 |
Why?
|
| Aorta, Abdominal | 1 | 2009 | 152 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2012 | 953 | 0.020 |
Why?
|
| Pelvis | 1 | 2009 | 362 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 866 | 0.020 |
Why?
|
| Microspheres | 1 | 2007 | 210 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2012 | 1450 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1165 | 0.020 |
Why?
|
| Matched-Pair Analysis | 1 | 2006 | 103 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2007 | 305 | 0.020 |
Why?
|
| Phenotype | 1 | 2018 | 6295 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2009 | 291 | 0.020 |
Why?
|
| Linear Models | 1 | 2009 | 1085 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2017 | 4078 | 0.020 |
Why?
|
| Southwestern United States | 1 | 2006 | 62 | 0.020 |
Why?
|
| Survival | 1 | 2006 | 177 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2006 | 409 | 0.020 |
Why?
|
| Internet | 1 | 2009 | 706 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2013 | 1823 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 3203 | 0.020 |
Why?
|
| Brain | 1 | 2018 | 4113 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2006 | 980 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2007 | 551 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 6086 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 6009 | 0.010 |
Why?
|
| Lymph Node Excision | 1 | 2011 | 1959 | 0.010 |
Why?
|
| Postoperative Complications | 1 | 2018 | 5542 | 0.010 |
Why?
|
| Length of Stay | 1 | 2007 | 1900 | 0.010 |
Why?
|
| Multiple Myeloma | 1 | 2012 | 2138 | 0.010 |
Why?
|
| Cytokines | 1 | 2009 | 2809 | 0.010 |
Why?
|
| Communication | 1 | 2007 | 876 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 2359 | 0.010 |
Why?
|
| Radiometry | 1 | 2004 | 980 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2012 | 14551 | 0.010 |
Why?
|
| Liver | 1 | 2006 | 2961 | 0.010 |
Why?
|